Full Press Release Details
("Midatech" or the "Company")
Midatech (AIM: MTPH.L; NASDAQ: MTP), the
R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces that
Stephen Stamp, Chief Financial Officer and a Director of the Company, has purchased 250,000 ordinary shares of 0.005 pence each
in the Company ("Share(s)") at a price of 5.5 pence per Share.
Following the purchase, Mr Stamp's holding
in the Company is 450,000 Shares, representing 0.11 per cent. of the Company's issued share capital.
The notification below, made in accordance
with the requirements of the EU Market Abuse Regulation, provides further detail.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Stephen Stamp | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Financial Officer | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Midatech Pharma plc | |||
| b) | LEI | 549300GKR2G40H3QFY57 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of 0.005 pence each in Midatech Pharma plc | |||
| Identification code | GB00BRTL9B63 | ||||
| b) | Nature of the transaction | Sale and purchase of ordinary shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 5.5p per share | 250,000 | ||||
| d) | Aggregated information | ||||
| - Aggregated volume | N/A - single transaction | ||||
| - Price | |||||
| e) | Date of the transaction | 2 October 2019 | |||
| f) | Place of the transaction | London Stock Exchange - AIM |
contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
For more information, please contact:
| Midatech Pharma PLC |
| Dr Craig Cook, CEO Stephen Stamp, CFO |
| Tel: +44 (0)1235 888300 |
| www.midatechpharma.com |
| Panmure Gordon (UK) Limited (Nominated Adviser and Broker) |
| Freddy Crossley, Emma Earl (Corporate Finance) |
| James Stearns (Corporate Broking) |
| Tel: +44 (0)20 7886 2500 |
| IFC Advisory Limited (Financial PR and UK Investor Relations) |
| Tim Metcalfe / Graham Herring |
| Tel: +44 (0)20 3934 6630 |
| Email: midatech@investor-focus.co.uk |
| Westwicke Partners (US Investor Relations) |
| Chris Brinzey |
| Tel: +1 339 970 2843 |
| Email: chris.brinzey@westwicke.com |
PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving
delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery
technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of
patients undergoing treatment for life threatening diseases.
developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of
disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation
of the potential for each platform:
platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended
period of time (from weeks to months).
platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly
and locally into tumours.
platform: a leading edge nano-technology used for targeting medications to sites of disease.
By improving biodelivery
and biodistribution of approved existing molecules, Midatech's unique R&D has the potential to make medicines better,
lower technical risks, accelerate regulatory approval and route to market, and provide newly patentable products. The platform
nature of the technologies allows the potential to develop multiple drug assets rather than being reliant on a limited number of
Midatech's headquarters
and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com